Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

EyePoint, Inc. - Common Stock (NQ:EYPT)

16.86 -0.57 (-3.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about EyePoint, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
The Great Rotation: Small Caps Lead the Charge as 2026 Trading Opens
As the opening bells of 2026 ring across Wall Street, a definitive shift in market leadership is unfolding. In the first trading sessions of the new year, the Russell 2000 index, a benchmark for... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Small-Cap Renaissance: Why 2026 is the Year of the Russell 2000 and XSU
As the sun rises on January 1, 2026, the financial landscape is witnessing a profound shift that many analysts have anticipated for years: the definitive return of the U.S. small-cap sector. After a... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Analyst Expectations For EyePoint Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
A Peek at EyePoint Pharmaceuticals's Future Earnings ↗
 
Via Benzinga
News headline image
The 2026 Horizon: Technical Breakouts Signal a Sustained Bull Run in AI and Energy
As the final trading bell of 2025 rings, the financial markets are closing the year on a high note, characterized by a series of powerful technical breakouts across several high-growth sectors. The S&P... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
EyePoint (EYPT) Q3 2025 Earnings Call Transcript ↗
EyePoint (EYPT) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviews ↗
 
Via Benzinga
News headline image
Analyst Ratings For EyePoint Pharmaceuticals ↗
 
Via Benzinga
News headline image
EyePoint Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) Shares Drop on Q3 Earnings and Revenue Miss ↗
EyePoint Pharmaceuticals stock falls after Q3 2025 earnings miss estimates. Despite the financial setback, its key DURAVYU trials for wet AMD are fully enrolled and on track for 2026 data. 
Via Chartmill
Topics Earnings
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study ↗
EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding. 
Via Benzinga
News headline image
EyePoint (EYPT) Q2 Revenue Drops 44% ↗
Via The Motley Fool
News headline image
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) Q2 2025 Earnings Miss Estimates as Shares Drop 4.5% Pre-Market ↗
EyePoint Pharmaceuticals (EYPT) Q2 2025 earnings miss estimates with $5.33M revenue and -$0.85 EPS, sparking a 4.5% pre-market drop. Clinical progress in DURAVYU Phase 3 trial offers hope amid... 
Via Chartmill
Topics Earnings
News headline image
Forecasting The Future: 4 Analyst Projections For EyePoint Pharmaceuticals ↗
 
Via Benzinga
News headline image
Breakout Momentum Plays You May Not Know About
Momentum investing is all about timing—these three under-the-radar stocks have begun to rise by still seem to have room for further growth. 
Via MarketBeat
News headline image
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 5, 2025 ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
These stocks are moving in today's pre-market session ↗
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss ↗
EyePoint Pharmaceuticals' shares rise as interim Phase 2 VERONA trial data shows Duravyu improves visual acuity and anatomy in diabetic macular edema patients. 
Via Benzinga
News headline image
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
NVIDIA, Trump Media & Technology, Bausch + Lomb, Sirius XM And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
Topics Government
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.